Tumor Biology

, Volume 36, Issue 11, pp 8755–8760 | Cite as

Prognosis of invasive breast cancer after adjuvant therapy evaluated with VEGF microvessel density and microvascular imaging

  • Ying Li
  • Xi Wei
  • Sheng zhang
  • Jin Zhang
Research Article


The aim of this study was to investigate the role of ultrasonographic microvascular imaging in the evaluation of prognosis of patients with invasive breast cancer treated by adjuvant therapies. A total of 121 patients with invasive breast cancer underwent ultrasonographic contrast-enhanced imaging, vascular endothelial growth factor (VEGF) staining, and microvessel density (MVD) counts. The parameters of microvascular imaging and the expression of VEGF and MVD in primary breast cancer were calculated. The correlation between these factors and the overall and progression-free survival rate were analyzed using the Kaplan-Meier method. Among 121 cases, the positive VEGF cases were 75 and negative ones were 46. The cut point of 52.3 was calculated by the regressive curve for MVD counts. The data showed the mean intensity (MI) was positively associated with both the MVD counts (r = .51, p < .001) and VEGF expression (r = .35, p < .001). For the prognosis of patients, high VEGF expression and MVD counts were associated with reduced progressive and survival times (PFS, p = .032 and p = .034; OS, p = .041 and p = .038, respectively). The correlation between parameters of microvascular imaging, VEGF expressive status, and the MVD counts were established. The cut point of mean intensity (MI = 40) was used to investigate as an independent predictor for PFS (p = .021) and OS (p = .025), respectively, due to a strong correlation between MVD counts and VEGF expression in patients with invasive breast cancer. The microvascular imaging could be a visual and helpful tool to predict the prognosis of patients with invasive breast cancer treated by adjuvant therapies.


Invasive breast cancer VEGF MVD Microvascular imaging Adjuvant therapy 



This work is supported by a grant from the National Natural Science Foundation of China (No. 81401412).


  1. 1.
    Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–89.CrossRefPubMedGoogle Scholar
  2. 2.
    Fox S, Leek R, Smith K, Hollyer J, Greenall M, Harris A. Tumor angiogenesis in node-negative breast carcinomas-relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat. 1994;29:109–16.CrossRefPubMedGoogle Scholar
  3. 3.
    Weidner N, Semple J, Welch W, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Hansen S, Grabau D, Sorensen F, Bak M, Vach W, Rose C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res. 2000;6:139–46.PubMedGoogle Scholar
  5. 5.
    Wei X, Li Y, Zhang S, Ming G. Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS). Tumour Biol. 2014;35(7):6521–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res. 1986;46:467–73.PubMedGoogle Scholar
  7. 7.
    Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Bosari S, Lee AKC, De Lellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantification and prognosis in invasive breast carcinoma. Hum Pathol. 1992;23:755–61.CrossRefPubMedGoogle Scholar
  9. 9.
    Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, et al. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013;19(5):1281–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Linardou H, Kalogeras KT, Kronenwett R, Kouvatseas G, Wirtz RM, Zagouri F, et al. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Breast Cancer Res. 2012;14(6):R145.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wei X, Li Y, Zhang S, Xin XJ, Zhu L, Gao M. The role of contrast-enhanced ultrasound (CEUS) in the early assessment of microvascularization in patients with aggressive B-cell lymphoma treated by rituximab-CHOP: a preliminary study. Clin Hemorheol Microcirc. 2014;58(2):363–76.PubMedGoogle Scholar
  12. 12.
    Xu Y, Zhang S, Wei X, Pan Y, Hao J. Contrast enhanced ultrasonography prediction of cystic renal mass in comparison to histopathology. Clin Hemorheol Microcirc. 2014;58(3):429–38.PubMedGoogle Scholar
  13. 13.
    Uehiro N, Horii R, Iwase T, Tanabe M, Sakai T, Morizono H, et al. Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer. Breast Cancer. 2014;21(6):748–53.CrossRefPubMedGoogle Scholar
  14. 14.
    Koutras A, Kotoula V, Fountzilas G. Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer. Pharmacogenomics. 2015;16(1):79–94.CrossRefPubMedGoogle Scholar
  15. 15.
    Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000;5:37–44.CrossRefPubMedGoogle Scholar
  16. 16.
    Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer. 1993;55:371–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol. 2000;18(7):1423–31.CrossRefPubMedGoogle Scholar
  18. 18.
    Arapandoni-Dadioti P, Giatromanolaki A, Trihia H, Harris AL, Koukourakis M. Angiogenesis in ductal breast carcinoma. Comparison of microvessel density between primary tumour and lymph node metastasis. Cancer Lett. 1999;137:145–50.CrossRefPubMedGoogle Scholar
  19. 19.
    Schindl M, Schoppmann S, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002;8:1831–7.PubMedGoogle Scholar
  20. 20.
    Blackwell K, Dewhirst M, Liotcheva V, Snyder S, Broadwater G, Bentley R, et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res. 2004;10:4083–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Wei X, Li Y, Zhang S, Li X, Wang H, Yong X, et al. Evaluation of microvascularization in focal salivary gland lesions by contrast-enhanced ultrasonography (CEUS) and Color Doppler sonography. Clin Hemorheol Microcirc. 2013;54(3):259–71.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.The Third Department of Breast Cancer, National Clinical Research Center of Cancer, Ministry of Education, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and HospitalTianjinChina
  2. 2.Department of Diagnostic and Therapeutic Ultrasonography, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and TherapyTianjin Medical University Cancer Institute and HospitalTianjinChina

Personalised recommendations